GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ampio Pharmaceuticals Inc (OTCPK:AMPE) » Definitions » Current Ratio

Ampio Pharmaceuticals (Ampio Pharmaceuticals) Current Ratio : 2.41 (As of Dec. 2023)


View and export this data going back to 2003. Start your Free Trial

What is Ampio Pharmaceuticals Current Ratio?

The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Ampio Pharmaceuticals's current ratio for the quarter that ended in Dec. 2023 was 2.41.

Ampio Pharmaceuticals has a current ratio of 2.41. It generally indicates good short-term financial strength.

The historical rank and industry rank for Ampio Pharmaceuticals's Current Ratio or its related term are showing as below:

AMPE' s Current Ratio Range Over the Past 10 Years
Min: 1.93   Med: 5.55   Max: 13.93
Current: 2.41

During the past 13 years, Ampio Pharmaceuticals's highest Current Ratio was 13.93. The lowest was 1.93. And the median was 5.55.

AMPE's Current Ratio is ranked worse than
63.69% of 1556 companies
in the Biotechnology industry
Industry Median: 3.735 vs AMPE: 2.41

Ampio Pharmaceuticals Current Ratio Historical Data

The historical data trend for Ampio Pharmaceuticals's Current Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ampio Pharmaceuticals Current Ratio Chart

Ampio Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Current Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.93 10.08 6.96 11.18 2.41

Ampio Pharmaceuticals Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Current Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 11.18 4.02 3.67 3.37 2.41

Competitive Comparison of Ampio Pharmaceuticals's Current Ratio

For the Biotechnology subindustry, Ampio Pharmaceuticals's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ampio Pharmaceuticals's Current Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ampio Pharmaceuticals's Current Ratio distribution charts can be found below:

* The bar in red indicates where Ampio Pharmaceuticals's Current Ratio falls into.



Ampio Pharmaceuticals Current Ratio Calculation

The current ratio is mainly used to give an idea of the company's ability to pay back its short-term liabilities with its short-term assets.

Ampio Pharmaceuticals's Current Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Current Ratio (A: Dec. 2023 )=Total Current Assets (A: Dec. 2023 )/Total Current Liabilities (A: Dec. 2023 )
=5.736/2.376
=2.41

Ampio Pharmaceuticals's Current Ratio for the quarter that ended in Dec. 2023 is calculated as

Current Ratio (Q: Dec. 2023 )=Total Current Assets (Q: Dec. 2023 )/Total Current Liabilities (Q: Dec. 2023 )
=5.736/2.376
=2.41

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Ampio Pharmaceuticals  (OTCPK:AMPE) Current Ratio Explanation

The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.

Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.

The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.

If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.


Ampio Pharmaceuticals Current Ratio Related Terms

Thank you for viewing the detailed overview of Ampio Pharmaceuticals's Current Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Ampio Pharmaceuticals (Ampio Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
373 Inverness Parkway, Suite 200, Englewood, CO, USA, 80112
Ampio Pharmaceuticals Inc is a biopharmaceutical company. It is focused on the clinical development of Ampion and preclinical development. Its product candidate, Ampion, is in clinical trials and is being developed for the treatment of severe Osteoarthritis of the Knee, an intravenous treatment for COVID-19 patients, and an inhaled treatment for COVID-19-induced respiratory distress.
Executives
J Kevin Buchi director 41 MOORES ROAD, FRAZER PA 19355
Michael A Martino director C/O AMBIT BIOSCIENCES CORPORATION, 11080 ROSELLE STREET, SAN DIEGO CA 92121
David R Stevens director 300 ELLIOTT AVENUE WEST, SUITE 500, SEATTLE WA 98119-4114
Elizabeth Varki Jobes director 640 LEE ROAD, CHESTERBROOK PA 19087
Philip H Coelho director C/O THERMOGENESIS CORP, 2711 CITRUS ROAD, RANCHO CORDOVA CA 95742
Holli Cherevka officer: Chief Operating Officer C/O AMPIO PHARMACEUTICALS, INC., 373 IVERNESS PARKWAY, ENGLEWOOD CO 80112
Dan Stokely officer: CFO 4810 EASTGATE MALL, SAN DIEGO CA 92121
Chilcott, Iii Thomas E. officer: Chief Financial Officer 373 INVERNESS PARKWAY, ENGLEWOOD CO 80122
Gregory A Gould officer: Chief Financial Officer 1111 MAIN STREET, SUITE 660, VANCOUVER WA 98660
Joshua R. Disbrow officer: Chief Operating Officer AMPIO PHARMACEUTICALS, INC., 5445 DTC PARKWAY, SUITE 925, GREENWOOD VILLAGE CO 80111
Michael Macaluso director C/O AMPIO PHARMACEUTICALS, INC., 5445 DTC PARKWAY, SUITE 925, GREENWOOD VILLAGE CO 80111
Richard B Giles director 5445 DTC PARKWAY, SUITE 925, GREENWOOD VILLAGE CO 80111
David Bar-or director, officer: Chief Scientific Officer C/O AMPIO PHARMACEUTICALS, INC., 373 INVERNESS PARKWAY, SUITE 200, ENGLEWOOD CO 80112
Vaughan Lennox Clift officer: Chief Regulatory Affairs 807 NOBLE SPRINGS ROAD, HOUSTON TX 77062
Mark D Mcgregor officer: Chief Financial Officer 5445 DTC PARKWAY, SUITE 925, GREENWOOD VILLAGE CO 80111